Top

Published in:

Open Access 01-12-2013 | Review article

The omics in migraine

Authors: Luana Lionetto, Giovanna Gentile, Elisa Bellei, Matilde Capi, Donata Sabato, Francesco Marsibilio, Maurizio Simmaco, Luigi Alberto Pini, Paolo Martelletti

Published in: The Journal of Headache and Pain | Issue 1/2013

Abstract

The term omics consist of three main areas of molecular biology, such as genomics, proteomics and metabolomics. The omics synergism recognise migraine as an ideal study model, due to its multifactorial nature. In this review, the plainly research data featuring in this complex network are reported and analyzed, as single or multiple factor in pathophysiology of migraine. The future of migraine biomolecular research shall be focused on networking among these different and hierarchical disciplines. We have to look for its Ariadne’s tread, in order to see the whole painting of migraine molecular biology.

Available only for authorised users

Simmaco M, Borro M, Missori S, Martelletti P: Pharmacogenomics in migraine: catching biomarkers for a predictable disease control. Expert Rev Neurother 2009,9(9):1267–1269. 10.1586/ern.09.80PubMedCrossRef

Chen T, Murrell M, Fowdar J, Roy B, Grealy R, Griffiths LR: Investigation of the role of the GABRG2 gene variant in migraine. J Neurol Sci 2012,318(1–2):112–114. 15 10.1016/j.jns.2012.03.014PubMedCrossRef

Carreño O, Corominas R, Fernández-Morales J, Camiña M, Sobrido MJ, Fernández-Fernández JM, Pozo-Rosich P, Cormand B, Macaya A: SNP variants within the vanilloid TRPV1 and TRPV3 receptor genes are associated with migraine in the Spanish population. Am J Med Genet B Neuropsychiatr Genet 2012,159B(1):94–103. 10.1002/ajmg.b.32007PubMedCrossRef

Geppetti P, Rossi E, Chiarugi A, Benemei S: Antidromic vasodilatation and the migraine mechanism. J Headache Pain 2012,13(2):103–111. 10.1007/s10194-011-0408-3PubMedCentralPubMedCrossRef

Cox HC, Lea RA, Bellis C, Carless M, Dyer T, Blangero J, Griffiths LR: Variants in the human potassium channel gene (KCNN3) are associated with migraine in a high risk genetic isolate. J Headache Pain 2011,12(6):603–608. 10.1007/s10194-011-0392-7PubMedCentralPubMedCrossRef

Cox HC, et al.: A genome-wide analysis of 'Bounty' descendants implicates several novel variants in migraine susceptibility. Neurogenetics 2012,13(3):261–266. 10.1007/s10048-012-0325-xPubMedCentralPubMedCrossRef

Maher BH, Lea RA, Benton M, Cox HC, Bellis C, Carless M, Dyer TD, Curran J, Charlesworth JC, Buring JE, Kurth T, Chasman DI, Ridker PM, Schürks M, Blangero J, Griffiths LR: An X chromosome association scan of the Norfolk Island genetic isolate provides evidence for a novel migraine susceptibility locus at Xq12. PLoS One 2012,7(5):e37903. 10.1371/journal.pone.0037903PubMedCentralPubMedCrossRef

Schürks M: Genetics of migraine in the age of genome-wide association studies. J Headache Pain 2012,13(1):1–9. 10.1007/s10194-011-0399-0PubMedCentralPubMedCrossRef

Ligthart L, de Vries B, Smith AV, Ikram MA, Amin N, Hottenga JJ, Koelewijn SC, Kattenberg VM, de Moor MH, Janssens AC, Aulchenko YS, Oostra BA, de Geus EJ, Smit JH, Zitman FG, Uitterlinden AG, Hofman A, Willemsen G, Nyholt DR, Montgomery GW, Terwindt GM, Gudnason V, Penninx BW, Breteler M, Ferrari MD, Launer LJ, van Duijn CM, van den Maagdenberg AM, Boomsma DI: Meta-analysis of genome-wide association for migraine in six population-based European cohorts. Eur J Hum Genet 2011,19(8):901–907. 10.1038/ejhg.2011.48PubMedCentralPubMedCrossRef

10.

Sintas C, Carreño O, Fernández-Morales J, Cacheiro P, Sobrido MJ, Narberhaus B, Pozo-Rosich P, Macaya A, Cormand B: A replication study of a GWAS finding in migraine does not identify association in a Spanish case–control sample. Cephalalgia 2012,32(14):1076–1080. 10.1177/0333102412457090PubMedCrossRef

11.

Esserlind AL, Kirchmann M, Hauge AW, Le H, Olesen J: A genotype-phenotype analysis of the 8q22.1 variant in migraine with aura. Eur J Neurol 2012,19(4):603–609. 10.1111/j.1468-1331.2011.03588.xPubMedCrossRef

12.

Menon S, et al.: The human μ-opioid receptor gene polymorphism (A118G) is associated with head pain severity in a clinical cohort of female migraine with aura patients. J Headache Pain 2012,13(7):513–519. 10.1007/s10194-012-0468-zPubMedCentralPubMedCrossRef

13.

Tana C, Tafuri E, Tana M, Martelletti P, Negro A, Affaitati G, Fabrizio A, Costantini R, Mezzetti A, Giamberardino MA: New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters? J Headache Pain 2013,14(1):9. 1 10.1186/1129-2377-14-9PubMedCentralPubMedCrossRef

14.

Menon S, Lea RA, Roy B, Hanna M, Wee S, Haupt LM, Oliver C, Griffiths LR: Genotypes of the MTHFR C677T and MTRR A66G genes act independently to reduce migraine disability in response to vitamin supplementation. Pharmacogenet Genom 2012,22(10):741–9. 10.1097/FPC.0b013e3283576b6bCrossRef

15.

Scher AI, Terwindt GM, Verschuren WM, et al.: Migraine and MTHFR C677T genotype in a population-based sample. Ann Neurol 2006,59(2):372–375. 10.1002/ana.20755PubMedCrossRef

16.

Samaan Z, Gaysina D, Cohen-Woods S, Craddock N, Jones L, Korszun A, Owen M, Mente A, McGuffin P, Farmer A: Methylenetetrahydrofolate reductase gene variant (MTHFR C677T) and migraine: a case control study and meta-analysis. BMC Neurol 2011, 11: 66. 2 10.1186/1471-2377-11-66PubMedCentralPubMedCrossRef

17.

Roecklein KA, Scher AI, Smith A, Harris T, Eiriksdottir G, Garcia M, Gudnason V, Launer LJ: Haplotype analysis of the folate-related genes MTHFR, MTRR, and MTR and migraine with aura. Cephalalgia 2013,33(7):469–482. 10.1177/0333102413477738PubMedCentralPubMedCrossRef

18.

Miao J, Wang F, Fang Y: Association of 231G > A polymorphism of endothelin type A receptor gene with migraine: a meta-analysis. J Neurol Sci 2012,323(1–2):232–235. 15 10.1016/j.jns.2012.09.027PubMedCrossRef

19.

Gentile G, Missori S, Borro M, Sebastianelli A, Simmaco M, Martelletti P: Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. J Headache Pain 2010,11(2):151–156. 10.1007/s10194-010-0202-7PubMedCentralPubMedCrossRef

20.

Gentile G, Borro M, Lala N, Missori S, Simmaoc M, Martelletti P: Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. J Headache Pain 2010,11(5):431–435. 10.1007/s10194-010-0241-0PubMedCentralPubMedCrossRef

21.

Aldred S, Grant MM, Griffiths HR: The use of proteomics for the assessment of clinical samples in research. Clin Biochem 2004, 37: 943–952. 10.1016/j.clinbiochem.2004.09.002PubMedCrossRef

22.

Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS: Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005, 4: 409–418. 10.1074/mcp.M500006-MCP200PubMedCrossRef

23.

Gao Y, Holland RD, Yu LR: Quantitative proteomics for drug toxicity. Briefings Funct Genomics Proteomics 2009,8(2):158–166. 10.1093/bfgp/elp006CrossRef

24.

Wetmore BA, Merrick BA: Toxicoproteomics: proteomics applied to toxicology and pathology. Toxicol Phatol 2004, 32: 619–642.CrossRef

25.

Bellei E, Cuoghi A, Monari E, Bergamini S, Fantoni LI, Zappaterra M, Guerzoni S, Bazzocchi A, Tomasi A, Pini LA: Proteomic analysis of urine in medication-overuse headache patients: possibile relation with renal damages. J Headache Pain 2012, 13: 45–52. 10.1007/s10194-011-0390-9PubMedCentralPubMedCrossRef

26.

Bellei E, Monari E, Cuoghi A, Bergamini S, Guerzoni S, Ciccarese M, Ozben T, Tomasi A, Pini LA: Discovery by a proteomic approach of possible early biomarkers of drug-induced nephrotoxicity in medication-overuse headache. J Headache Pain 2013, 14: 6. 10.1186/1129-2377-14-6PubMedCentralPubMedCrossRef

27.

Robbins L: Frequent triptan use: observations on safety issues. Headache 2004, 44: 178–182. 10.1111/j.1526-4610.2004.04037.xPubMedCrossRef

28.

Taber SS, Pasko DA: The epidemiology of drug-induced disorders: the kidney. Expert Opin Drug Saf 2008,7(6):679–690. 10.1517/14740330802410462PubMedCrossRef

29.

Gonzáles-Buitrago JM, Ferreira L, Lorenzo I: Urinary proteomics. Clin Chim Acta 2007, 375: 49–56. 10.1016/j.cca.2006.07.027CrossRef

30.

Sleno L, Emili A: Proteomic methods for drug target discovery. Curr Opin Chem Biol 2008, 12: 46–54. 10.1016/j.cbpa.2008.01.022PubMedCrossRef

31.

Waring WS, Moonie A: Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol 2011, 49: 720–728. 10.3109/15563650.2011.615319CrossRef

32.

Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ: Brainstem activation specific to migraine headache. Lancet 2001,357(9261):1016–1017. 31 10.1016/S0140-6736(00)04250-1PubMedCrossRef

33.

Vanmolkot FH, de Hoon JN: Increased C-reactive protein in young adult patients with migraine. Cephalalgia 2007,27(7):843–846. 10.1111/j.1468-2982.2007.01324.xPubMedCrossRef

34.

Welch KM, Brandes AW, Salerno L, Brandes JL: C-reactive protein may be increased in migraine patients who present with complex clinical features. Headache 2006,46(2):197–199. 10.1111/j.1526-4610.2006.00330.xPubMedCrossRef

35.

Turan H, Horasanli B, Ugur M, Arslan H: Procalcitonin levels in migraine patients. Can J Neurol Sci 2011,38(1):124–128.PubMedCrossRef

36.

Guldiken S, Guldiken B, Demir M, Kabayel L, Ozkan H, Turgut N, Hunkar R, Kat S: Soluble CD40 ligand and prolactin levels in migraine patients during interictal period. J Headache Pain 2011,12(3):355–360. 10.1007/s10194-011-0306-8PubMedCentralPubMedCrossRef

37.

Turner MK, Hooten WM, Schmidt JE, Kerkvliet JL, Townsend CO, Bruce BK: Prevalence and clinical correlates of vitamin D inadequacy among patients with chronic pain. Pain Med 2008,9(8):979–984. 10.1111/j.1526-4637.2008.00415.xPubMedCrossRef

38.

Prakash S, Mehta NC, Dabhi AS, Lakhani O, Khilari M, Shah ND: The prevalence of headache may be related with the latitude: a possible role of Vitamin D insufficiency? J Headache Pain 2010,11(4):301–307. 10.1007/s10194-010-0223-2PubMedCentralPubMedCrossRef

39.

Kjaergaard M, Eggen AE, Mathiesen EB, Jorde R: Association Between Headache and Serum 25-Hydroxyvitamin D; the Tromsø Study: Tromsø 6. Headache 2012., 13: 10.1111/j.1526-4610.2012.02250.x

40.

Thompson SW, Bennett DL, Kerr BJ, Bradbury EJ, McMahon SB: Brain-derived neurotrophic factor is an endogenous modulator of nociceptive responses in the spinal cord. Proc Natl Acad Sci USA 1999,96(14):7714–7718. 6 10.1073/pnas.96.14.7714PubMedCentralPubMedCrossRef

41.

Fischer M, Wille G, Klien S, Shanib H, Holle D, Gaul C, Broessner G: Brain-derived neurotrophic factor in primary headaches. J Headache Pain 2012,13(6):469–475. 10.1007/s10194-012-0454-5PubMedCentralPubMedCrossRef

42.

Tanure MT, Gomez RS, Hurtado RC, Teixeira AL, Domingues RB: Increased serum levels of brain-derived neurotropic factor during migraine attacks: a pilot study. J Headache Pain 2010,11(5):427–430. 10.1007/s10194-010-0233-0PubMedCentralPubMedCrossRef

43.

Bittšanský M, Výbohová D, Dobrota D: Proton magnetic resonance spectroscopy and its diagnostically important metabolites in the brain. Gen Physiol Biophys 2012,31(1):101–112. 10.4149/gpb_2012_007PubMedCrossRef

44.

Sarchielli P, Tarducci R, Presciutti O, Gobbi G, Pelliccioli GP, Stipa G, Alberti A, Capocchi G: Functional 1H-MRS findings in migraine patients with and without aura assessed interictally. NeuroImage 2005,24(4):1025–1031. 15 10.1016/j.neuroimage.2004.11.005PubMedCrossRef

45.

Reyngoudt H, De Deene Y, Descamps B, Paemeleire K, Achten E: 1H-MRS of brain metabolites in migraine without aura: absolute quantification using the phantom replacement technique. Magn Reson Mater Phys 2010,23(4):227–241. 10.1007/s10334-010-0221-zCrossRef

46.

Reyngoudt H, Paemeleire K, Dierickx A, Descamps B, Vandemaele P, De Deene Y, Achten E: Does visual cortex lactate increase following photic stimulation in migraine without aura patients? A functional (1)H-MRS study. J Headache Pain 2011,12(3):295–302. 10.1007/s10194-011-0295-7PubMedCentralPubMedCrossRef

47.

Dichgans M, Herzog J, Freilinger T, Wilke M, Auer DP: 1H-MRS alterations in the cerebellum of patients with familial hemiplegic migraine type 1. Neurology 2005,64(4):608–613. 10.1212/01.WNL.0000151855.98318.50PubMedCrossRef

48.

De Tommaso M, Ceci E, Pica C, Trojano M, Delussi M, Franco G, Livrea P, Ruggieri M: Serum levels of N-acetyl-aspartate in migraine and tension-type headache. J Headache Pain 2012,13(5):389–394. 10.1007/s10194-012-0448-3PubMedCentralPubMedCrossRef

49.

Lionetto L, Capi M, Vignaroli G, Negro A, Martelletti P: Deciphering the task of N-acetyl aspartate in migraine. Expert Rev Neurother 2012,12(9):1057–1059. 10.1586/ern.12.97PubMedCrossRef

Title: The omics in migraine
Authors: Luana Lionetto
Giovanna Gentile
Elisa Bellei
Matilde Capi
Donata Sabato
Francesco Marsibilio
Maurizio Simmaco
Luigi Alberto Pini
Paolo Martelletti
Publication date: 01-12-2013
Publisher: Springer Milan
Published in: The Journal of Headache and Pain / Issue 1/2013
Print ISSN: 1129-2369
Electronic ISSN: 1129-2377
DOI: https://doi.org/10.1186/1129-2377-14-55

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The omics in migraine

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2013

Short lasting activity-related headaches with sudden onset in children: a case-based reasoning on classification and diagnosis

Headache and comorbidity in children and adolescents

Monozygotic twin sisters discordant for familial hemiplegic migraine

Spontaneous intracerebral hemorrhage in CADASIL

Migraine before rupture of intracranial aneurysms

Migraineurs with exercise-triggered attacks have a distinct migraine